Unique ID issued by UMIN | UMIN000011676 |
---|---|
Receipt number | R000013653 |
Scientific Title | Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study |
Date of disclosure of the study information | 2013/09/08 |
Last modified on | 2015/09/07 13:51:48 |
Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study
Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study
Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study
Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study
Japan |
Gastroesophageal reflux disease
Gastroenterology |
Others
NO
To compare the resolution of symptoms with esomeprazole 20mg/day or rabeprazole 10mg/day in gastroesophageal reflux disease patients.
Safety,Efficacy
Resolution Rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks
Improvement rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks
Interventional
Cross-over
Randomized
Cluster
Open -no one is blinded
Active
2
Treatment
Medicine |
Esomeprazole20mg/day1,14days
Rabeprazole10mg/day,14days
20 | years-old | <= |
Not applicable |
Male and Female
(1)Patients who have freely given written consent to participating in the study after receiving a full explanation (written and oral) of the study.
(2)Patients of either sex who are at least 20 years of age.
(3)Patients whose are taking medication of Proton pump inhibitors or Histamine 2 Receptor Antagonists already can be washout of these medications for one week.
(1)Patients with a history of gastrointestinal resection or vagotomy
(2)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, bloody disease, cardiac disease or malignant disease.
(3)Women who are pregnant or who may possibly be pregnant, and lactating mothers
(4)Other patients whom the investigator considers unsuitable for admission to the study
200
1st name | |
Middle name | |
Last name | Motoyasu chibai |
Heiwadai clinic
Surgery
4-26-8,Heiwadai,Nerima-ku,Tokyo,Japan
03-5922-1241
bk2m-cbi@asahi-net.or.jp
1st name | |
Middle name | |
Last name | Motoyasu chibai |
Heiwadai clinic
Surgery
4-26-8,Heiwadai,Nerima-ku,Tokyo,Japan
03-5922-1241
bk2m-cbi@asahi-net.or.jp
Heiwadai clinic
None
Self funding
NO
2013 | Year | 09 | Month | 08 | Day |
Published
Completed
2013 | Year | 08 | Month | 21 | Day |
2013 | Year | 09 | Month | 25 | Day |
2013 | Year | 09 | Month | 07 | Day |
2015 | Year | 09 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013653
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |